Biomarker analysis to predict the pathological response to neoadjuvant chemotherapy in locally advanced gastric cancer: An exploratory biomarker study of COMPASS, a randomized phase II trial.

Oshima T, Yoshikawa T, Miyagi Y, Morita S, Yamamoto M, Tanabe K, Nishikawa K, Ito Y, Matsui T, Kimura Y, Yokose T, Hiroshima Y, Aoyama T, Hayashi T, Ogata T, Cho H, Rino Y, Masuda M, Tsuburaya A, Sakamoto J

Open source

DOI: 10.18632/oncotarget.27658
Published: 2020 Jul 28
Container: Oncotarget
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.18632/oncotarget.27658,
  title = {Biomarker analysis to predict the pathological response to neoadjuvant chemotherapy in locally advanced gastric cancer: An exploratory biomarker study of COMPASS, a randomized phase II trial.},
  author = {Oshima T and Yoshikawa T and Miyagi Y and Morita S and Yamamoto M and Tanabe K and Nishikawa K and Ito Y and Matsui T and Kimura Y and Yokose T and Hiroshima Y and Aoyama T and Hayashi T and Ogata T and Cho H and Rino Y and Masuda M and Tsuburaya A and Sakamoto J},
  year = {2020},
  journal = {Oncotarget},
  doi = {10.18632/oncotarget.27658},
  url = {https://doi.org/10.18632/oncotarget.27658}
}

RIS

TY  - JOUR
TI  - Biomarker analysis to predict the pathological response to neoadjuvant chemotherapy in locally advanced gastric cancer: An exploratory biomarker study of COMPASS, a randomized phase II trial.
AU  - Oshima T
AU  - Yoshikawa T
AU  - Miyagi Y
AU  - Morita S
AU  - Yamamoto M
AU  - Tanabe K
AU  - Nishikawa K
AU  - Ito Y
AU  - Matsui T
AU  - Kimura Y
AU  - Yokose T
AU  - Hiroshima Y
AU  - Aoyama T
AU  - Hayashi T
AU  - Ogata T
AU  - Cho H
AU  - Rino Y
AU  - Masuda M
AU  - Tsuburaya A
AU  - Sakamoto J
PY  - 2020
JO  - Oncotarget
DO  - 10.18632/oncotarget.27658
UR  - https://doi.org/10.18632/oncotarget.27658
ER  -

APA

T, O., T, Y., Y, M., S, M., M, Y., K, T., K, N., Y, I., T, M., Y, K., T, Y., Y, H., T, A., T, H., T, O., H, C., Y, R., M, M., A, T., & J, S. (2020). Biomarker analysis to predict the pathological response to neoadjuvant chemotherapy in locally advanced gastric cancer: An exploratory biomarker study of COMPASS, a randomized phase II trial.. Oncotarget. https://doi.org/10.18632/oncotarget.27658

Source records

pubmed · retrieved 2026-09-26T10:49:15.721Z